S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
The 3-Stock Retirement Blueprint (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
The 3-Stock Retirement Blueprint (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
The 3-Stock Retirement Blueprint (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Why CSL Ltd Stock Could Be Worth a Look
The 3-Stock Retirement Blueprint (Ad)
MarketBeat: Week in Review 11/28 – 12/02
Estonia to buy US rocket artillery system in $200M deal
The 3-Stock Retirement Blueprint (Ad)
Rail workers say deal won't resolve quality-of-life concerns
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
NASDAQ:MACK

Merrimack Pharmaceuticals - MACK Stock Forecast, Price & News

$11.88
+0.03 (+0.25%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.79
$12.18
50-Day Range
$3.01
$12.51
52-Week Range
$3.00
$13.66
Volume
112,359 shs
Average Volume
1.99 million shs
Market Capitalization
$159.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MACK stock logo

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Stock News Headlines

Merrimack Reports Third Quarter 2022 Financial Results
Merrimack Pharmaceuticals (NASDAQ: MACK)
Merrimack Pharmaceuticals: Out For Now
Merrimack Pharmaceuticals GAAP EPS of -$0.01
Merrimack Reports Full Year 2021 Financial Results
Merrimack Pharmaceuticals reports FY results
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings
5/10/2019
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
N/A

Profitability

Net Income
$-2,450,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.98 per share

Miscellaneous

Free Float
9,950,000
Market Cap
$159.31 million
Optionable
Optionable
Beta
1.90

Key Executives

  • Mr. Gary L. Crocker M.B.A.Mr. Gary L. Crocker M.B.A. (Age 70)
    MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
    Comp: $105.44k
  • Dr. Ulrik B. Nielsen Ph.D. (Age 50)
    Co-Founder & Independent Director
    Comp: $102.76k
  • Dr. Anthony J. Sinskey Ph.D. (Age 82)
    Sc.D., Co-Founder and Scientific Advisor
  • Geoffrey Grande C.F.A.
    Sr. Director of Communications
  • Ms. Ellen K. Forest (Age 58)
    Head of HR
  • Dr. Fazal R. Khan Ph.D. (Age 72)
    Sr. VP of Manufacturing
  • Dr. Daryl C. Drummond Ph.D. (Age 53)
    Head of Research
  • Mr. Timothy R. Surgenor (Age 62)
    Sec.













MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2022?

Merrimack Pharmaceuticals' stock was trading at $3.91 on January 1st, 2022. Since then, MACK shares have increased by 203.8% and is now trading at $11.88.
View the best growth stocks for 2022 here
.

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 844,700 shares, an increase of 226.0% from the October 31st total of 259,100 shares. Based on an average daily trading volume, of 625,900 shares, the short-interest ratio is currently 1.3 days. Currently, 7.5% of the shares of the stock are sold short.
View Merrimack Pharmaceuticals' Short Interest
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.14.

When did Merrimack Pharmaceuticals' stock split?

Shares of Merrimack Pharmaceuticals reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (8.21%), Dimensional Fund Advisors LP (3.52%), Nantahala Capital Management LLC (3.20%), Sepio Capital LP (2.20%), BlackRock Inc. (1.54%) and Two Sigma Investments LP (0.16%). Insiders that own company stock include Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends
.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $11.88.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $159.31 million. The biopharmaceutical company earns $-2,450,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Merrimack Pharmaceuticals have?

The company employs 426 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-441-1000, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 12/3/2022 by MarketBeat.com Staff